# OnCo record neopact (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/neopact/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "neopact", "NCT03639948" ;
  schema:name "NeoPACT"@en ;
  schema:description "NeoPACT tested a shorter, anthracycline-free pre-operative combination of carboplatin, docetaxel and pembrolizumab in triple-negative breast cancer. Tumours disappeared completely in 58 percent of women and 86 percent were free of events at three years, which is the basis for the SCARLET phase 3 comparison with the KEYNOTE-522 regimen."@en ;
  schema:url <https://onco.cc/trials/neopact/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03639948>, <https://doi.org/10.1001/jamaoncol.2023.5033> ;
  onco:status "positive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-early/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/platinum/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/pegfilgrastim/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:terms <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/rcb/>, <https://onco.cc/terms/tils/>, <https://onco.cc/terms/de-escalation/> ;
  onco:trials <https://onco.cc/trials/scarlet-s2212/>, <https://onco.cc/trials/keynote-522/> .